NorthWest Biotherapeutics Inc (NWBO)

[wavelengthy]

Presenting in the video above is Keyoumars Ashkan, the chief European investigator for Dcvax-L P3. Dr. Ashkan works at Kings College London. Speaking before Linda on Sep 27 is Farzin Farzaneh, a colleague of Dr. Ashkan.

From Northwest PR:
https://www.nwbio.com/wp-content/uploads/2013/06/press2012.04.12.pdf
“We are pleased to be leading the way in bringing these novel immune therapies to patients in the
UK,” commented Dr. Keyoumars Ashkan, Consultant (i.e., Specialist) Neurosurgeon, Reader
(Associate Professor) in Neurosurgery and Lead for Neuro-Oncology at King’s College
Hospital. “Brain cancers are some of the most lethal cancers, and there is a great need for new and
better treatments. The positive data from the Phase I clinical trials in the U.S. were very
encouraging in delaying disease progression and extending survival times, without significant
toxic side effects. We are hopeful that similar results will be seen in the large, randomized clinical
trial which we are now helping to bring to the UK.”

Farzin Farzaneh, Professor of Molecular Medicine and head of cGMP cell product manufacturing
at King’s College London, said: “At King’s, we are excited to be undertaking the manufacturing
for the DCVax® immune therapies in the UK. Such immune therapies represent an exciting new
class of products, and we are pleased to apply our expertise and facilities for cell therapy to help
bring DCVax® immune therapies to the UK and Europe.”